Idarubicin

DB01177

small molecule approved

Deskripsi

An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.

Struktur Molekul 2D

Berat 497.4939
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 22 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

The drug is eliminated predominately by biliary and to a lesser extent by renal excretion, mostly in the form of idarubicinol.

Interaksi Obat

1027 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Idarubicin.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Idarubicin.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Idarubicin.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Idarubicin.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Idarubicin.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Idarubicin.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Idarubicin.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Idarubicin.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Idarubicin.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Idarubicin.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Idarubicin.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Idarubicin.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Idarubicin.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Idarubicin.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Idarubicin.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Idarubicin.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Idarubicin.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Idarubicin.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Idarubicin.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Idarubicin.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Idarubicin.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Idarubicin.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Idarubicin.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Idarubicin.
Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Idarubicin.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Idarubicin.
Cladribine Idarubicin may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Idarubicin.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Idarubicin.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Idarubicin.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Idarubicin.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Idarubicin.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Idarubicin.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Idarubicin.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Idarubicin.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Idarubicin.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Idarubicin.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Idarubicin.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Idarubicin.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Idarubicin.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Idarubicin.
Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Idarubicin.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Idarubicin.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Idarubicin.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Idarubicin.
Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Idarubicin.
Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Idarubicin.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Idarubicin.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Idarubicin.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Idarubicin.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Idarubicin.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Idarubicin.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Idarubicin.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Idarubicin.
Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Idarubicin.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Idarubicin.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Idarubicin.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Idarubicin.
Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Idarubicin.
Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Idarubicin.
Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Idarubicin.
Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Idarubicin.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Idarubicin.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Idarubicin.
Imatinib The serum concentration of Idarubicin can be increased when it is combined with Imatinib.
Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Idarubicin.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Idarubicin.
Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Idarubicin.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Idarubicin.
Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Idarubicin.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Idarubicin.
Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Idarubicin.
Tretinoin The risk or severity of cardiotoxicity can be increased when Tretinoin is combined with Idarubicin.
Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Idarubicin.
Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Idarubicin.
Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Idarubicin.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Idarubicin.
Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Idarubicin.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Idarubicin.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Idarubicin.
Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Idarubicin.
Sirolimus The risk or severity of adverse effects can be increased when Sirolimus is combined with Idarubicin.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Idarubicin.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Idarubicin.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Idarubicin.
Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Idarubicin.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Idarubicin.
Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Idarubicin.
Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Idarubicin.
Doxorubicin The risk or severity of adverse effects can be increased when Doxorubicin is combined with Idarubicin.
Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Idarubicin.
Busulfan The risk or severity of adverse effects can be increased when Busulfan is combined with Idarubicin.
Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Idarubicin.
Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Idarubicin.
Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Idarubicin.
Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Idarubicin.
Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Idarubicin.
Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Idarubicin.
Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Idarubicin.
Trilostane The risk or severity of adverse effects can be increased when Trilostane is combined with Idarubicin.

Target Protein

DNA topoisomerase 2-beta TOP2B
DNA
DNA topoisomerase 2-alpha TOP2A

Referensi & Sumber

Synthesis reference: Marco Villa, Roberto Arosio, Roberta Fretta, Nicola Diulgheroff, "Synthesis of idarubicin aglycone." U.S. Patent US20060047108, issued March 02, 2006.

Contoh Produk & Brand

Produk: 39 • International brands: 0
Produk
  • Aj-idarubicin
    Solution • 1 mg / mL • Intravenous • Canada • Generic • Approved
  • Idamycin
    Injection, powder, lyophilized, for solution • 1 mg/1mL • Intravenous • US • Approved
  • Idamycin - Cap 10mg
    Capsule • 10 mg • Oral • Canada • Approved
  • Idamycin - Cap 25mg
    Capsule • 25 mg • Oral • Canada • Approved
  • Idamycin - Cap 5mg
    Capsule • 5 mg • Oral • Canada • Approved
  • Idamycin PFS
    Solution • 1 mg/1mL • Intravenous • US • Approved
  • Idamycin PFS
    Solution • 1 mg/1mL • Intravenous • US • Approved
  • Idamycin PFS
    Solution • 1 mg/1mL • Intravenous • US • Approved
Menampilkan 8 dari 39 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul